COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,582 Articles (22,415 medRxiv, 8,167 bioRxiv)

Most recent first Previous |  Page 1383: Articles 13821-13830  | Next

Electoral processes and COVID-19 infections in Japan
Murata, S., Nagata, T., Ogata, S., Nishimura, K., Hagihara, A.
10.1101/2021.06.13.21258864 — Posted: 2021-06-15
Study on the mucosal and serological immune response to the Novel Coronavirus (SARS-CoV-2) vaccine
Chan, R. W., Liu, S., Cheung, J. Y., Tsun, J. G., Chan, K. C., Chan, K. Y., Fung, G. P., Li, A. M., Lam, H. S.
10.1101/2021.06.15.21256661 — Posted: 2021-06-15
Estimating decay curves of neutralising antibodies to SARS-CoV-2 infection
Poehler, M., Gibson, L., Lustig, A., Moreland, N. J., McGregor, R., James, A.
10.1101/2021.06.13.21258857 — Posted: 2021-06-15
Deep Mutational Scanning of Dynamic Interaction Networks in the SARS-CoV-2 Spike Protein Complexes: Allosteric Hotspots Control Functional Mimicry and Resilience to Mutational Escape
Verkhivker, G.
10.1101/2021.06.15.448568 — Posted: 2021-06-15
Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens
Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu-Omar, A., Schneitler, S., Becker, S. L., Gaertner, B. C., Sester, U., Sester, M.
10.1101/2021.06.13.21258859 — Posted: 2021-06-15
SARS-CoV-2 Spike protein binding of glycated serum albumin - its potential role in the pathogenesis of the COVID-19 clinical syndromes and bias towards individuals with pre-diabetes/type 2 diabetes & metabolic diseases.
Iles, J. K., Zmuidinaite, R., Saddee, C., Gardiner, A., Lacy, J., Harding, S., Ule, J., Roblett, D., Heeney, J. L., Baxendale, D. H., Iles, R. K.
10.1101/2021.06.14.21258871 — Posted: 2021-06-15
Antibody response after a single dose of ChAdOx1-nCOV (Covishield) vaccine in subjects with prior SARS-CoV2 infection: Is a single dose sufficient?
Borkakoty, B., Sarmah, M. D., Bhattacharjee, C. K., Bali, N., Gogoi, G.
10.1101/2021.06.15.21258346 — Posted: 2021-06-15 Discussion: Onsite
VAERS data reveals no increased risk of neuroautoimmune adverse events from COVID-19 vaccines
von Csefalvay, C.
10.1101/2021.06.13.21258851 — Posted: 2021-06-15
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials
Martins-Filho, P. R., Ferreira, L. C., Heimfarth, L., Araujo, A. A. d. S., Quintans-Junior, L. J.
10.1101/2021.06.12.21258831 — Posted: 2021-06-15
SARS-CoV-2 variant of concern B.1.1.7: diagnostic accuracy of three antigen-detecting rapid tests
Lindner, A. K., Krüger, L. J., Nikolai, O., Klein, J. A. F., Rössig, H., Schnitzler, P., Corman, V. M., Jones, T. C., Tobian, F., Gaeddert, M., Burock, S., Sacks, J. A., Seybold, J., Mockenhaupt, F. P., Denkinger, C. M.
10.1101/2021.06.15.21258502 — Posted: 2021-06-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).